Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 15671 | 26.5901 |
09:34 ET | 2153 | 26.73 |
09:36 ET | 2099 | 26.71 |
09:38 ET | 9887 | 26.805 |
09:39 ET | 2571 | 26.79 |
09:41 ET | 1187 | 26.77 |
09:43 ET | 1402 | 26.72 |
09:45 ET | 1384 | 26.71 |
09:48 ET | 900 | 26.7 |
09:50 ET | 3983 | 26.66 |
09:52 ET | 3287 | 26.69 |
09:54 ET | 1814 | 26.71 |
09:56 ET | 5379 | 26.755 |
09:57 ET | 700 | 26.76 |
09:59 ET | 2071 | 26.74 |
10:01 ET | 2200 | 26.76 |
10:03 ET | 5315 | 26.81 |
10:06 ET | 6487 | 26.84 |
10:08 ET | 2900 | 26.855 |
10:10 ET | 6621 | 26.84 |
10:12 ET | 1457 | 26.835 |
10:14 ET | 7269 | 26.82 |
10:15 ET | 10064 | 26.77 |
10:17 ET | 5406 | 26.7 |
10:19 ET | 2544 | 26.695 |
10:21 ET | 2475 | 26.685 |
10:24 ET | 9901 | 26.685 |
10:26 ET | 39369 | 26.69 |
10:28 ET | 25438 | 26.685 |
10:30 ET | 4833 | 26.685 |
10:32 ET | 4785 | 26.695 |
10:33 ET | 7107 | 26.68 |
10:35 ET | 13320 | 26.675 |
10:37 ET | 2337 | 26.68 |
10:39 ET | 3597 | 26.685 |
10:42 ET | 10170 | 26.68 |
10:44 ET | 1621 | 26.68 |
10:46 ET | 3758 | 26.6602 |
10:48 ET | 4913 | 26.6952 |
10:50 ET | 5478 | 26.67 |
10:51 ET | 11640 | 26.705 |
10:53 ET | 5043 | 26.675 |
10:55 ET | 4157 | 26.685 |
10:57 ET | 1300 | 26.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 15.9B | 15.0x | +1.83% |
Amneal Pharmaceuticals Inc | 2.0B | -11.4x | --- |
Catalent Inc | 10.2B | -8.7x | --- |
Jazz Pharmaceuticals PLC | 6.8B | 22.1x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Prestige Consumer Healthcare Inc | 3.4B | 16.7x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.9B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.15% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.46 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 15.0x |
Price/Sales (TTM) | 7.1 |
Price/Cash Flow (TTM) | 13.3x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.